Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | KIFC1 | Q9BW19 | 10/20 | 0.51 |
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30497107 | 0.84 | L3MBTL1 (0.70) | L3MBTL1KIFC1TP53MAPTPOLB | |
| SCHEMBL225165 | 0.84 | L3MBTL1 (0.70) | L3MBTL1KIFC1TP53MAPTPOLB | |
| SCHEMBL326777 | 0.82 | L3MBTL1 (0.68) | L3MBTL1KIFC1TP53MAPTPOLB | |
| SCHEMBL1020649 | 0.82 | L3MBTL1 (0.68) | L3MBTL1KIFC1TP53MAPTPOLB | |
| SCHEMBL30454185 | 0.82 | L3MBTL1 (0.68) | L3MBTL1KIFC1TP53MAPTPOLB | |
| SCHEMBL1300650 | 0.80 | L3MBTL1 (0.64) | L3MBTL1KIFC1TP53MAPTPOLB | |
| SCHEMBL25813767 | 0.80 | PLK1 (0.69) | L3MBTL1KIFC1TP53MAPTPOLB | |
| SCHEMBL13028749 | 0.80 | L3MBTL1 (0.64) | L3MBTL1KIFC1TP53MAPTPOLB | |
| SCHEMBL13130238 | 0.79 | L3MBTL1 (1.00) | L3MBTL1TP53MAPTPOLBPLK1 | |
| SCHEMBL20646906 | 0.79 | MAPT (0.51) | L3MBTL1KIFC1TP53MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120715-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120715-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | L3MBTL1 1425/4885KIFC1 4652/4885TP53 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.